Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.
The booming weight-loss drug market is being led by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The last 2 weeks have seen Zepbound just edge past Wegovy in the number of prescriptions made in the US, as well as a major partnership announcement with Amazon.com.
Amazon.com’s pharmacy unity will deliver drug prescriptions of Zepbound made through Eli Lilly’s direct-to-consumer service LillyDirect. LillyDirect was launched in January 2024 to enable access to migraine, diabetes, and obesity drugs for patients directly from the company via online pharmacy Truepill. With the Amazon.com partnership, prescriptions made to LillyDirect will now either be filled and delivered by Amazon Pharmacy or Truepill. Orders will be split between the two companies.
Surging demand for weight-loss drugs such as Zepbound and Wegovy was the impetus for LillyDirect launching. The market is expected to reach US$100 billion by the end of the 2020s. A spokesperson for the drugmaker states that they “looked forward to continuing to enhance LillyDirect with additional medicines, partners, and service providers in the near future.”
The demand for weight-loss drug products does not seem to be slowing any time soon – on March 15, data from IQVIA revealed that new prescriptions for Zepbound reached over 77,000 in the US. This would be the first time prescriptions for Zepbound have surpassed Wegovy since their respective launches. Zepbound launched in the US in December 2023, over 2 years after Wegovy’s approval.
Earlier this month, Wegovy was approved in the US for the indication of reducing risk of strokes and heart attacks in overweight or obese adults. Eli Lilly also produces the diabetes drug Mounjaro, which contains the same API as Zepbound. Mounjaro is forecasted by GlobalData to be the top-selling GLP-1 product by 2029.
Sources:
1. Lilly partners with Amazon to deliver Zepbound and other drugs [Accessed March 19, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-weight-loss-drug-zepbound-new-us-prescriptions-surpass-wegovy-first-time-2024-03-15/
2. Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time [Accessed March 19, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-weight-loss-drug-zepbound-new-us-prescriptions-surpass-wegovy-first-time-2024-03-15/
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance